These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 20113945)
21. Radical retropubic prostatectomy for localized prostate cancer in renal transplant patients. Antonopoulos IM; Nahas WC; Piovesan AC; Falci R; Kanashiro H; Alvarez GA; Srougi M Urology; 2008 Dec; 72(6):1362-5. PubMed ID: 18485460 [TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. Krambeck AE; DiMarco DS; Rangel LJ; Bergstralh EJ; Myers RP; Blute ML; Gettman MT BJU Int; 2009 Feb; 103(4):448-53. PubMed ID: 18778350 [TBL] [Abstract][Full Text] [Related]
23. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764 [TBL] [Abstract][Full Text] [Related]
24. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095 [TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Melton GB; Fazio VW; Kiran RP; He J; Lavery IC; Shen B; Achkar JP; Church JM; Remzi FH Ann Surg; 2008 Oct; 248(4):608-16. PubMed ID: 18936574 [TBL] [Abstract][Full Text] [Related]
26. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
27. Endoscopic extraperitoneal radical prostatectomy after previous transurethral resection of prostate: oncologic and functional outcomes of 100 cases. Do M; Haefner T; Liatsikos E; Kallidonis P; Hicks J; Dietel A; Horn LC; Rabenalt R; Stolzenburg JU Urology; 2010 Jun; 75(6):1348-52. PubMed ID: 19914701 [TBL] [Abstract][Full Text] [Related]
28. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762 [TBL] [Abstract][Full Text] [Related]
32. Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan. Miyake H; Sakal I; Harada K; Eto H; Hara I Hinyokika Kiyo; 2004 Mar; 50(3):151-6. PubMed ID: 15148765 [TBL] [Abstract][Full Text] [Related]
33. Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. Carini M; Masieri L; Minervini A; Lapini A; Serni S Eur Urol; 2008 Mar; 53(3):554-61. PubMed ID: 17683854 [TBL] [Abstract][Full Text] [Related]
34. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml. Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384 [TBL] [Abstract][Full Text] [Related]
35. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719 [TBL] [Abstract][Full Text] [Related]
36. Evolution of the clinical presentation and outcomes after radical prostatectomy for patients with clinically localized prostate cancer--changing trends over a ten year period. Stimac G; Dimanovski J; Trnski D; Katusić J; Ruzić B; Spajić B; Reljić A; Padovan M; Kraus O Coll Antropol; 2007 Dec; 31(4):1055-60. PubMed ID: 18217458 [TBL] [Abstract][Full Text] [Related]
37. Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy. Pierorazio PM; Spencer BA; McCann TR; McKiernan JM; Benson MC Urology; 2007 Oct; 70(4):717-22. PubMed ID: 17991543 [TBL] [Abstract][Full Text] [Related]
38. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P; Katcher J; Levin H; Zippe C; Klein E Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737 [TBL] [Abstract][Full Text] [Related]
39. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759 [TBL] [Abstract][Full Text] [Related]
40. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]